Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.02 Billion CNY | -17.28% |
| 2022 | 2.45 Billion CNY | -3.93% |
| 2021 | 2.55 Billion CNY | 21.24% |
| 2020 | 2.1 Billion CNY | 51.79% |
| 2019 | 1.38 Billion CNY | 44.8% |
| 2018 | 957.2 Million CNY | 69.23% |
| 2017 | 565.61 Million CNY | 142.55% |
| 2016 | 233.19 Million CNY | 20.85% |
| 2015 | 192.96 Million CNY | 46.65% |
| 2014 | 131.57 Million CNY | 43.3% |
| 2013 | 91.82 Million CNY | -0.51% |
| 2012 | 92.29 Million CNY | 53.18% |
| 2011 | 60.25 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.99 Billion CNY | 0.44% |
| 2024 Q3 | 1.98 Billion CNY | -0.43% |
| 2024 Q1 | 1.98 Billion CNY | -1.87% |
| 2023 Q1 | 2.24 Billion CNY | -8.34% |
| 2023 FY | 2.02 Billion CNY | -17.28% |
| 2023 Q4 | 2.02 Billion CNY | -9.68% |
| 2023 Q3 | 2.24 Billion CNY | 1.46% |
| 2023 Q2 | 2.21 Billion CNY | -1.52% |
| 2022 Q4 | 2.45 Billion CNY | -0.22% |
| 2022 Q3 | 2.45 Billion CNY | -3.06% |
| 2022 Q1 | 2.72 Billion CNY | 6.82% |
| 2022 Q2 | 2.53 Billion CNY | -7.02% |
| 2022 FY | 2.45 Billion CNY | -3.93% |
| 2021 Q2 | 2.17 Billion CNY | -1.35% |
| 2021 Q3 | 2.32 Billion CNY | 6.74% |
| 2021 Q4 | 2.55 Billion CNY | 9.71% |
| 2021 Q1 | 2.2 Billion CNY | 4.95% |
| 2021 FY | 2.55 Billion CNY | 21.24% |
| 2020 Q1 | 1.59 Billion CNY | 15.07% |
| 2020 FY | 2.1 Billion CNY | 51.79% |
| 2020 Q3 | 1.91 Billion CNY | 34.21% |
| 2020 Q2 | 1.43 Billion CNY | -10.33% |
| 2020 Q4 | 2.1 Billion CNY | 9.61% |
| 2019 FY | 1.38 Billion CNY | 44.8% |
| 2019 Q4 | 1.38 Billion CNY | 7.45% |
| 2019 Q3 | 1.28 Billion CNY | -2.29% |
| 2019 Q2 | 1.32 Billion CNY | 16.18% |
| 2019 Q1 | 1.13 Billion CNY | 18.72% |
| 2018 Q2 | 772.58 Million CNY | 22.51% |
| 2018 Q1 | 630.63 Million CNY | 11.5% |
| 2018 Q3 | 771.14 Million CNY | -0.19% |
| 2018 FY | 957.2 Million CNY | 69.23% |
| 2018 Q4 | 957.2 Million CNY | 24.13% |
| 2017 Q3 | 494.66 Million CNY | 37.16% |
| 2017 FY | 565.61 Million CNY | 142.55% |
| 2017 Q4 | 565.61 Million CNY | 14.34% |
| 2017 Q2 | 360.65 Million CNY | 61.24% |
| 2017 Q1 | 223.67 Million CNY | -4.08% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 233.19 Million CNY | 20.85% |
| 2016 Q4 | 233.19 Million CNY | -6.88% |
| 2016 Q2 | 218.91 Million CNY | 0.0% |
| 2016 Q3 | 250.4 Million CNY | 14.39% |
| 2015 Q4 | 192.96 Million CNY | 0.0% |
| 2015 FY | 192.96 Million CNY | 46.65% |
| 2014 FY | 131.57 Million CNY | 43.3% |
| 2013 FY | 91.82 Million CNY | -0.51% |
| 2012 FY | 92.29 Million CNY | 53.18% |
| 2011 FY | 60.25 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 8.84 Billion CNY | 77.082% |
| Joinn Laboratories(China)Co.,Ltd. | 1.67 Billion CNY | -21.264% |
| WuXi AppTec Co., Ltd. | 17.66 Billion CNY | 88.527% |
| Autobio Diagnostics Co., Ltd. | 2.85 Billion CNY | 29.042% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.19 Billion CNY | 36.56% |
| Chemclin Diagnostics Co., Ltd. | 431.76 Million CNY | -369.494% |